Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

NCT04196465 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Subjects With Resectable and Localized Gastric Cancer
Subjects With Resectable Esophageal Cancer or Liver Cancer
Subjects With Resectable Liver Cancer

Interventions

DRUG: IMC-001

Sponsor

Asan Medical Center